Abstract:Acute myeloid leukemias (AMLs) are infrequent, yet highly malignant neoplasms responsible for a large number of cancer-related deaths. The incidence has been near stable over the last years. It continuously shows 2 peaks in occurrence in early childhood and later adulthood. With an incidence of 3.7 per 100,000 persons and an age-dependent mortality of 2.7 to nearly 18 per 100,000 persons, there is a rising awareness in the Western world of AML's special attributes resulting from an ever-aging population. To objectively describe epidemiologic data on this patient population, recent publications were evaluated to make transparent the current trends and facts. A review of the literature is presented, reflecting highlights of current research with respect to AML etiology. To estimate outcome and discuss informed treatment decisions with AML patients of different age groups and different biologic risk categories, it is mandatory to consider that the outcome results reported in clinical trials were until now heavily biased toward younger patients, whereas the overall dismal prognosis documented in population-based studies most likely reflects the exclusion of older patients from aggressive treatment. The etiology for most cases of AML is unclear, but a growing knowledge concerning leukemogenenic agents within chemotherapy regimens for other malignancies is already available. This includes specific associations of the most frequent balanced translocations in AML, including the "good-risk" abnormalities comprised by the core binding factor leukemias (i.e., AML with the translocation (8;21) and inversion of chromosome 16, and acute promyelocytic leukemia with the translocation (15;17)). In contrast to these genetic alterations, epigenetic lesions, e.g., promoter silencing by hypermethylation of the p15/INK4b and other genes, are increasingly recognized as important in the pathogenesis of AML.

Pathophysiology of Acute Myeloid Leukemia (AML)

[Molecular mechanisms in the development of acute myeloid leukemia]

Acute myeloid leukemia: Epidemiology and etiology

Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

Research of gene mutation in acute myeloid leukemia: development and prospect

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Put in a “Ca2+ll” to Acute Myeloid Leukemia

Malignant progression of pre-leukemic disorders

Molecular and clinical significance of FLT3, NPM1, DNMT3A and TP53 mutations in acute myeloid leukemia patients

Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia

Deciphering Acute Myeloid Leukemia Associated Transcription Factors in Human Primary CD34+ Hematopoietic Stem/Progenitor Cells

The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression

Diagnosis, Response Assessment and Treatment Outcomes in Acute Myeloid Leukemia (AML)

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

Genetic basis of acute myeloid leukemia (AML): The most common molecular changes in patients with normal karyotype

Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter

Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

The epigenetic state of the cell of origin defines mechanisms of leukemogenesis

Acute Promyclocytic Leukemia: A Model Of Molecular Target Based Therapy